Breaking dogmata to help patients: non-myeloablative haematopoietic stem cell transplantation

Bibliography

• ALARCON-SEGOVIA D,RUIZ-ARGUELLES A, LLORENTE L: Broken dogma: Penetration of autoantibodies into living cells. Immunol. Today (1996) 17:163–164.
   PubMedGoogle Scholar
• THOMAS ED: Hematopoietic stem cell transplantation. Sci. Am. (1995) 272:38–47.
   Google Scholar
• ODOM LF, AUGUST CS, GITHENS JH et al: Remission of relapsed leukaemia during a graft-versus-host reaction. A 'graft-versus-leukaemia reaction' in man? Lancet (1978) 2(8089):537–540.
   Google Scholar
• WEIDEN PL, SULLIVAN KM, FLUORNOY N, STORB R, THOMAS ED: Antileukemic effect of chronic graft versus host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl.Med. (1981) 304:1529–1533.
   Google Scholar
• LICHTMAN MA, SPIVAK JL,BOXER LA, SHATTIL SJ,HENDERSON ES: Hematology: Landmark Papers of the Twentieth CenturyLichtman MA, Spivak JL, Boxer LA, Shattil SJ, Henderson ES (Eds), Academic Press, San Diego, USA (2000):741–747.
   Google Scholar
• KOLB HJ, MITTERMOLLER J, CLEMM CH et al.: Donor leukocyte transfusions for treatment of recurrent chromic myelogenous leukemia in marrow transplant patients. Blood (1990) 76:2462–2465.
   PubMed Web of Science ®Google Scholar
• SLAVIN S, NAPARSTEK E, NAGLER A, ACKERSTEIN A, KAPELUSHNIK J, OR R: Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp. Hematol (1995) 23:1553–1562.
   PubMed Web of Science ®Google Scholar
• SLAVIN S, NAPARSTEK E, NAGLER A et al.: Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemiarelapse after allogeneic bone marrow transplantation. Blood (1996) 87:2195–2204.
   PubMed Web of Science ®Google Scholar
• GIRALT S, ESTEY E, ALBITAR M et al:Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood (1997) 89:4531–4536.
   PubMed Web of Science ®Google Scholar
• SLAVIN S, NAGLER A, NAPARSTEK E et al.: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematological diseases. Blood (1998) 91:756–763.
   PubMed Web of Science ®Google Scholar
• QUESENBERRY PJ, STEWART FM, BECKER P et al.: Stem cell transplantation without myeloablation in immunocompetent recipients.In: Non-Myeloablative Stem Cell Transplantation. Giralt S, Slavin S (Eds), Darwin Scientific Publishing, Abingdon, Oxfordshire, UK (2000):11–16.
   Google Scholar
• KHOURI IF, KEATING M,KORBLING M et al.: Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. Clin. Oncol. (1998) 16:2817–2824.
   Google Scholar
• CHAMPLIN R.: Nonmyeloablative chemotherapy with allogeneic hematopoietic transplantation as adoptive immunotherapy for malignancies. In: Hematology 1999. Schechter GP, Hoffman R, Schrier SL (Eds), The American Society of Hematology Education Program Book, Washington, USA (1999):413–416.
   Google Scholar
• FEINSTEIN L, SANDMAIER B, MALONEY D et al.: Non-myeloablativehematopoietic stem cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect. Ann. NY Acad. Sci. (2001) 938:328–337.
   Google Scholar
• STORB R, CHAMPLIN R, RIDDELL SR, MURATA M, BRYANT S, WARREN EH: Non-myeloablative transplants for malignant disease. In: Hematology 2001. Schechter GP, Broudy VC, Williams ME (Eds), The American Society of Hematology Education Program Book, Washington, USA (2002):375–391.
   Google Scholar
• CHILDS R, BARRETT AJ:Graft-versus-tumor effects following non-myeoablative stem cell transplantation. In: Non-Myeloablative Stem Cell Transplantation. Giralt S, Slavin S (Eds), Darwin Scientific Publishing, Abingdon, Oxfordshire, UK (2000):13–126.
   Google Scholar
• CHILDS R, CLAVE E, TISDALE J, PLANTE M, HENSEL N, BARRET AJ: Succesful treatment of metastatic renal cell carcinoma with a non-myeloablative allogeneic peripheral blood progenitor cell transplant: evidence for a graft-versus-tumor effect.' Clin. Omni (1999) 17:2044–2051.
   PubMed Web of Science ®Google Scholar
• RUIZ-ARGUELLES GJ: Allogeneic stem cell transplantation using non-myeloablative conditioning regimens: results of the Mexican approach. Int. Hematol. (2002) 76\(Suppl. 1):376–379.
   Google Scholar
• GEORGES GE, STORB R: Review of `minitransplantation': nonmyeloablative allogeneic hematopoiteic stem cell transplantation. Int. Hematol. (2003) 77:3–14.
   PubMed Web of Science ®Google Scholar
• RUIZ-ARGUELLES GJ, RUIZ-ARGUELLES A, GOMEZ-ALMAGUER D et al: Features of the engraftment of allogeneic hematopoietic stem cells using reduced-intesity conditioning regimens. Leukemia Lymph. (2001) 42:145–150.
   PubMed Web of Science ®Google Scholar
• RUIZ-ARGOELLES GJ, GOMEZ-RANGEL JD, PONCE-DE-LEON S, GONZALEZ-DECTOR L, REYES-NO&EZ V, GARCES-EISELE J: The Mexican schedule to conduct allogeneic stem cell transplantation is related to a low risk of cytomegalovirus reactivation and disease. Am. Hematol (2004) 75:200–204.
   PubMed Web of Science ®Google Scholar
• RUIZ-ARGOELLES GJ, LOPEZ-MARTINEZ B, SANTELLAN-OLEA MR et al: Follow up of hemopoietic chimerism in individuals given allogeneic hemopoietic stem cell allografts using an immunosuppressive, non-myeloablative conditioning regimen: a prospective study in a single institution. Leak. Lymphoma (2002) 43:1509–1511.
   PubMed Web of Science ®Google Scholar
• RUIZ-ARGOELLES GJ, GOMEZ-ALMAGUER D, LOPEZ-MARTINEZ B, CANTO-RODRIGUEZ OG, JAIME-PEREZ JC, GONZALEZ-LLANO O: Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. Haematologica (2002) 87:894–896.
   PubMedGoogle Scholar
• GOMEZ-ALMAGUER D, RUIZ-ARGOELLES GJ, TARIN-ARZAGA LC et al: Reduced-intensity stem cell transplantation in children and adolescents: the Mexican experience. Biol. Blood Marrow Transpl. (2003) 9:157–161.
   PubMed Web of Science ®Google Scholar
• RUIZ-ARGOELLES GJ, LOPEZ-MARTINEZ B, GOMEZ-RANGEL D et al: Decreased transfusion requirements in patients given stem cell allografts using a non-myeloablative conditioning regimen: a single institution experience. Hematology (2003) 8:151–154.
   PubMedGoogle Scholar
• GOMEZ-ALMAGUER D, RUIZ-ARGOELLES GJ, RUIZ-ARGOELLES A, GONZALEZ-LLANO O, CANTO OE, HERNANDEZ NE: Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis. Bone Marrow Banspl. (2000) 25:131–133.
   PubMed Web of Science ®Google Scholar
• RUIZ-ARGOELLES GJ, GOMEZ-ALMAGUER D, RUIZ-ARGOELLES A, GONZALEZ-LLANO O, CANTO OG, JAIME-PEREZ JC: Results of anoutpatient-based stem cell allotransplant program using non-myeloablative conditioning regimens. Am. I Hematol (2001) 66:241–244.
   PubMedGoogle Scholar
• RUIZ-ARGOELLES GJ: Outpatient programs of myeloablative chemotherapy, autologous and allogeneic bone marrow transplantation. Haematologica (2000) 85:1233–1234.
   PubMedGoogle Scholar
• RUIZ-ARGOELLES GJ, LOPEZ-MARTINEZ B,LOPEZ-ARIZA B: Succesful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed Hodgkin's disease following autologous stem cell transplantation. Arch. Med. Res. (2003) 34:242–245.
   PubMed Web of Science ®Google Scholar
• RUIZ-ARGOELLES GJ, GOMEZ-RANGEL D, SANCHEZ-ANZALDO J, RUIZ-ARGOELLES A, PORRAS-RAMIREZ G, LUIS-LOPEZ A: Trasplante de células de cordon umbilical: informe de dos casos. Medicina Univ. (2002) 4:233–235.
   Google Scholar
• RUIZ-ARGOELLES GJ,GOMEZ-ALMAGUER D: The Mexican approach to conduct non-ablative stem cell transplantation should not be overlooked. Int. Hematol (2003) 77:526–527.
   PubMed Web of Science ®Google Scholar
• VINDELOV L: Allogeneic bone marrow transplantation with reduced conditioning. Eur. Haematol (2001) 66:73–82.
   PubMed Web of Science ®Google Scholar
• RUIZ-ARGOELLES GJ: 'The Mexican approach' to conduct non-myeloablative stem cell transplantation. Ear: .1 Haematol (2001) 67:5–6.
   Google Scholar
• CARELLA AM, LERMA E, DEJANA A et al.: Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias. Haematologica (1998) 83:904–909.
   PubMed Web of Science ®Google Scholar
• RUIZ-ARGUELLES GJ: Simplification, not demystification nor trivialization of stem cell transplantation. Haematologica (2001) 86:E07.
   PubMedGoogle Scholar
• RUIZ-ARGOELLES GJ: The graft-versus-tumor effect in chronic myelogenous leukemia. Rev Invest. CHn. Mex. (2002) 54:154–160.
   PubMed Web of Science ®Google Scholar
• RUIZ-ARGOELLES GJ, GOMEZ-ALMAGUER D, GOMEZ-RANGEL JD et al.: Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with acute leukemia eligible forconventional allografting: a prospective study. Leak. Lymphoma (2004) 45:1191–1195.
   PubMed Web of Science ®Google Scholar
• RUIZ-ARGOELLES GJ, GOMEZ-ALMAGUER D, GOMEZ-RANGEL JD et al.: Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with myeloid leukemias: results of a prospective study of the Latin American Cooperative Onco Hematology Group (LACOHG). Blood (2004) 104 (Suppl. I): (In Press).
   Google Scholar
• CHANDY M: Management of hematological diseases in developing countries: socio-economic aspects. In: Hematology 1999. Schechter GP, Hoffman R, Schrier SL (Eds), The American Society of Hematology Education Program Book, Washington, USA (1999):73–76.
   Google Scholar
• GOMEZ-ALMAGUER D: The simplification of the stem cell transplantation procedures in developing countries has resulted in cost-lowering and availability to more patients. Int. Hematol (2002) 76\(Suppl. 1):380–382.
   Google Scholar
• BARR RD: The importance of lowering costs of stem cell transplantation in devloping countries. Int. Hematol (2002) 76\(Suppl. 1):365–367.
   Google Scholar
• RUIZ-ARGOELLES GJ, RUIZ-REYES G: El tratamiento de las leucemias en paises en desarrollo. In: Actualizacion en Leucemias. Ruiz-Arguelles GJ, San-Miguel JF (Eds), Editorial Médica Panamericana, Mexico City, Mexico (1996):147–151.
   Google Scholar
• GIRALT S: Update of non-myeloablative stem cell transplantation for hematologic malignancies. Int. Hematol (2002) 76\(Suppl. 1):368–375.
   Google Scholar
• DJULBEGOVIC B, SEIDENFELD J, BONNELL A, KUMAR A: Nonmyeloablative allogeneic stem cell transplantion for hematologic malignancies: a systematic review. Cancer Control (2003) 10:17–41.
   PubMedGoogle Scholar
• SPITZER TR: The expanding applicationsof non-myeloablative stem cell transplantation. Pediam Transplant. (2003) 7:95–100
   PubMed Web of Science ®Google Scholar
• RUIZ-ARGOELLES GJ: Non-myeloablative bone marrow transplantation. Arch. Med. Res. (2003) 34:554–557.
   PubMed Web of Science ®Google Scholar
• COURIEL DR, SALIBA RM, GIRALT S et al.: Acute and chronic graft versus-host-disease after ablatrive and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol. Blood Marrow Transpl. (2004) 10:178–185.
   PubMed Web of Science ®Google Scholar
• RUIZ-ARGUELLES GJ, GOMEZ-ALMAGUER D, GOMEZ-MORALES E: Trasplante de células progenitoras hematopoyéticas. In: Hernatologia: Actualizacidn 2004. Gingora-Biachi R (Ed.), Edidones de la Agrupaci6n Mexicana para el Estudio de la Hematologia A.C., Merida, Mexico (2000139–148.Affiliation
   Google Scholar